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Abstract: Glucocerebrosidase (GCase) is a retaining β-glucosidase with acid pH optimum
metabolizing the glycosphingolipid glucosylceramide (GlcCer) to ceramide and glucose. Inherited
deficiency of GCase causes the lysosomal storage disorder named Gaucher disease (GD). In
GCase-deficient GD patients the accumulation of GlcCer in lysosomes of tissue macrophages is
prominent. Based on the above, the key function of GCase as lysosomal hydrolase is well recognized,
however it has become apparent that GCase fulfills in the human body at least one other key function
beyond lysosomes. Crucially, GCase generates ceramides from GlcCer molecules in the outer part
of the skin, a process essential for optimal skin barrier property and survival. This review covers
the functions of GCase in and beyond lysosomes and also pays attention to the increasing insight in
hitherto unexpected catalytic versatility of the enzyme.
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1. Introduction
The cellular acid β-glucosidase (EC 3.2.1.45) was first reported to be located in lysosomes more
than 50 years ago [1]. There it degrades the glycosphingolipid glucosylceramide (GlcCer), also known
as glucocerebroside (Figure 1A) [2]. The enzyme, commonly named glucocerebrosidase (GCase),
is active towards GlcCer molecules with different fatty acyl moieties. Deficiency of GCase causes
the recessively inherited disorder Gaucher disease (GD, OMIM #230800, ORPHA355), named after
the French dermatologist Ernest Gaucher, who published the first case report [3]. A hallmark of
GD are lipid-laden macrophages with lysosomal GlcCer deposits, referred to as Gaucher cells [4].
Numerous mutations in the GBA gene encoding GCase have been associated with GD [5]. The genetic
heterogeneity contributes to the highly variable clinical manifestation of the disorder that may involve
various organs and tissues [4]. A complete absence of GCase activity is incompatible with terrestrial
life due to a disturbed skin barrier [6,7]. The lethal impairment stems from the crucial extracellular role
of GCase in the stratum corneum (SC). This review covers the functions of GCase in the metabolism
of GlcCer inside lysosomes and beyond. First, Sections 2–5 deal with GCase as a cellular lysosomal
enzyme, and in the second part Section 6 onwards focuses on the extracellular function of GCase in
the skin.
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Figure  1.  (A)  Structure  of  glucosylceramide  (GlcCer)  and  degradation  by GCase  to  glucose  and 
ceramide.  (B)  Catalytic  activity  GCase:  Hydrolyzation  of  β‐glucosides  and  transglucosylation 
activity. (C) Occurrence of Gaucher cells and the biomarkers they secrete in plasma. (D) Metabolic 
adaptations  to GCase deficiency:  increase of GlcCer  as a  result of  lack of degradation by GCase. 
Accumulated  GlcCer  is  converted  by  ASAH1  to  glucosylsphingosine,  Glucosylated  cholesterol 
(GlcChol)  formed  by  GBA2  increases,  and  GM3  levels  rise  because  increased  anabolism  by 
glycosyltransferases  to  complex GSLs. Enzymes  are depicted  in  green. ASAH1:  acid  ceramidase, 
GBA2: cytosolic β‐glucosidase, GCase: β‐glucocerebrosidase, GCS: glucosylceramide synthase. 
Figure 1. (A) Structure of glucosylceramide (GlcCer) and degradation by GCase to glucose and
ceramide. (B) Catalytic activity GCase: Hydrolyzation of β-glucosides and transglucosylation activity.
(C) Occurrence of Gaucher cells and the biomarkers they secrete in plasma. (D) Metabolic adaptations
to GCase deficiency: increase of GlcCer as a result of lack of degradation by GCase. Accumulated
GlcCer is converted by ASAH1 to glucosylsphingosine, Glucosylated cholesterol (GlcChol) formed by
GBA2 increases, an GM3 levels rise because increased anabolism by glycosyltr nsferases to complex
GSLs. Enzyme are depicted in green. ASAH1: acid ceramidase, GBA2: cytosolic β-glucosidase, GCase:
β-glucocerebrosidase, GCS: glucosylc ramide synthase.
2. Part 1: GCase and Lysosomal Glucosylceramide Degradation
2.1. Glucosylceramide as Intermediate of Glycosphingolipids
The primary physiological substrate of GCase is GlcCer, the simplest glycosphingolipid (GSL) in
which a single glucose β-glucosidic is linked to the 1-hydroxy of ceramide (Cer) [8]. Figure 2 presents
an overview of the GSL metabolism. De novo formation of Cer starts on the endoplasmic reticulum (ER)
with formation of 3-keto-dihydrosphingosine by the enzyme serine palmitoyl transferase (SPT) that
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conjugates the amino acid serine with a palmitoyl chain [9–12]. Next, the enzyme 3-ketosphinganine
reductase (KSR) converts 3-keto-hydrosphingosine to dihydrosphingosine (sphinganine). Ceramide
synthases (CERS) are responsible for acylation of dihydrosphingosine, thus generating diverse
dihydroceramides [13–15]. In mammals six distinct CERS enzymes with different fatty acyl-CoA
affinities have been identified. Subsequently, dihydroceramide desaturase (DES) catalyzes the
conversion of dihydroceramides into ceramides 15. Ceramide is alternatively formed in the salvage
pathway by acylation of sphingosine molecules released from lysosomes [16,17]. Cer can be further
metabolized by conjugation of its 1-hydroxy, resulting in very diverse structures like ceramide
1-phosphate (C1P), sphingomyelin (SM), 1-O-acylceramide, galactosylceramide (GalCer), and GlcCer
(reviewed in [18]). Formation of GlcCer, the key GSL of this review, involves transfer of Cer to the
cytosolic surface of the Golgi apparatus where the membrane-bound glucosylceramide synthase (GCS)
generates GlcCer using UDP-glucose as sugar donor and Cer as acceptor [19,20]. Next, some of
the newly formed GlcCer molecules are converted back to Cer by the cytosol facing β-glucosidase
GBA2 [21], but most reach via an unknown mechanism the luminal membrane of the Golgi apparatus.
There, conversion to more complex GSLs like gangliosides and globosides occurs through stepwise
addition of additional sugar and sulfate moieties (the biosynthesis and vast structural heterogeneity of
GSL is excellently reviewed in [13,22]).
The major destination of newly formed GSLs is the outer leaflet of the plasma membrane. At the
cell surface, GSLs fulfill a variety of important functions. GSLs interact with cholesterol molecules
via hydrogen bonds and hydrophobic van der Waal’s forces and spontaneously form semi-ordered
lipid microdomains, commonly referred to as lipid rafts [23,24]. Hydrophilic cis-interactions among
GSL headgroups promote lateral associations with surrounding lipid and proteins. Residing in the
GSL-enriched domains are proteins involved in interactions of cells with the exterior (extracellular
space and other cells) and mediating the associated intracellular signaling processes [24–26]. The
GSL composition of lipid rafts may exert modulating effects in the cell’s response to triggers. One
example in this respect is the insulin receptor whose signaling is negatively influenced by neighboring
gangliosides such as GM3 in lipid rafts [27–29]. Pharmacological reduction of GSLs results in improved
glucose homeostasis in obese insulin-resistant rodents [30]. Similarly, the epidermal growth factor
(EGF) receptor is influenced by the GSL composition of microdomains in which it resides [31]. GSLs at
the cell surface also play direct roles in adhesion/recognition processes. For example, specific GSLs are
involved in binding of pathogenic viruses, microorganisms, and bacterial toxins [32,33]. The topic was
recently reviewed [34]. Glycosphingolipid-enriched lipid rafts essentially contribute to immunological
functions as, for example, activation of T cells [35–38].
2.2. Lysosomal Turnover of Glycosphingolipid
GSLs may exit cells from the plasma membrane through incorporation in high-density
lipoproteins [39,40]. However, most of the GSLs are internalized from the plasma membrane via
endocytosis involving multi-vesicular bodies within late endosomes. Similarly, exogenous GSLs, such
as constituents of lipoproteins or components of phagocytosed apoptotic cells, also reach lysosomes
by endocytic processes. Upon the delivery of internalized material to lysosomes, fragmentation of
GSL components takes place by step-wise removal of terminal sugars by specialized glycosidases.
The process is further assisted by accessory proteins such as saposins A-D and GM2 activator protein
(reviewed in [41]). The final lipid product of lysosomal fragmentation of GSLs, GalCer, and SM is in all
cases Cer [41]. The lysosomal acid ceramidase (EC 3.5.1.23) subsequently splits Cer into free fatty acid
and sphingosine to be exported to the cytosol [42]. The cytosolic sphingosine can then be used for the
formation of Cer or can be converted by sphingosine kinases (SK1 and SK2) to sphingosine-1-phosphate
(S1P) [43].
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3. Glucocerebrosidase
3.1. GCase Protein and Life Cycle
The penultimate step in GSL degradation is the deglucosylation of GlcCer yielding glucose and Cer.
This reaction is catalyzed by GCase, a 495 amino acid glycoprotein with four N-linked glycans [2,44].
GCase, based on its structural features, is classified in the glycoside hydrolase family GH30 (formerly
in the related family GH5) [45]. The 3-D structure of GCase was resolved by crystallography [46,47].
GCase, like other GH5 and GH30 glycosidases, has an (α/β)8 TIM barrel catalytic domain. In the case
of GCase this is fused with a β-structure consisting of an immunoglobulin-like fold [45]. GCase is a
retainingβ-glucosidase hydrolyzing a glucosidic substrate with net retention of glucose stereochemistry
(Figure 1B).
Retaining beta-glucosidases generally use a two-step catalytic mechanism. The Koshland double
displacement mechanism involves a catalytic nucleophile and acid/base residue [48]. A nucleophilic
attack to the anomeric carbon of the glycosidic substrate is the first step. The aglycon is released
assisted by a proton transfer from the acid/base residue and a covalent enzyme–glycoside complex
is formed. Next, an activated water molecule deglycosylates the nucleophile, allowing a new round
catalysis. The reaction involves two transient oxocarbenium ion-like states and the sugar substrate
adopts different itineraries depending on its pyranose ring configuration [49]. In the case of retaining
β-glucosidases like GCase, the substrate itinerary is 1S3 → 4H3 → 4C1 → 4H3 → 4C1 for the Michaelis
complex→ transition state→ covalent intermediate→ transition state→ product [50,51]. In the (α/β)8
TIM barrel catalytic domain of GCase, E340 acts as nucleophile and E235 as acid/base residue [52,53].
Cyclophellitol, present in the mushroom Phellinus sp., is a potent irreversible inhibitor that
binds covalently, in mechanism-based manner, to the nucleophile E340 of GCase [52–54]. The
structurally related compounds cyclophellitol aziridine and conduritol B-epoxide inactivate GCase
via the same mechanism [52,55]. Recently, superior suicide inhibitors for GCase were designed [56].
Cyclophellitol derivatives carrying a large hydrophobic substituent at C8 inactivate GCase with even
higher affinity and with great specificity (not reacting with another retaining β-glucosidase like GBA2
and GBA3) [56,57]. Using cyclophellitol as scaffold, selective activity-based probes (ABPs) toward
GCase were designed [52]. A reporter group (biotin or BODIPY) was attached to the C8 of cyclophellitol
via a pentyl linker rendering ABPs allowing ultrasensitive and specific visualization of GCase in vitro
and in vivo [58]. Subsequently, cyclophellitol aziridine ABPs with attached reporter groups via alkyl
or acyl linkers were designed reacting with multiple retaining glycosidases in the same class [55,59].
Cyclophellitol aziridine ABPs labeling α-galactosidases, α-glucosidases, α-fucosidase, α-iduronidase,
β-galactosidases, and β-glucuronidase, as well as cyclophellitol ABPs labelling galactocerebrosidase,
were designed [60–65]. Applications of ABPs are the quantitative detection and localization of
glycosidases in cells and tissues, as well as identification and characterization of glycosidase inhibitors
by competitive ABP profiling [66,67].
GCase shows an acid pH optimum of hydrolytic activity, coinciding with the lysosomal pH [44].
The activity of the enzyme towards GlcCer is promoted by negatively charged lipids and saposin C,
an activator protein generated in the lysosome by proteolytic processing of prosaposin [41,68]. The
half-life of GCase in lysosomes is relatively short due to proteolytic degradation by cathepsins as
suggested by the protective effect of leupeptin [69,70]. It was noted that unfolding and degradation of
GCase is protected by occupation of the catalytic pocket [69].
GCase fundamentally differs from other lysosomal hydrolases in the mechanism underlying
sorting and transport to lysosomes [44]. While most soluble lysosomal hydrolases are transported to
lysosomes by mannose-6-phosphate receptors, this is not the case for GCase. In the inherited disorders
mucolipidoses II and III, where formation of mannose-6-phosphate recognition signal in N-glycans of
lysosomal hydrolases is impaired and consequently these enzymes are largely secreted, the transport
of GCase to lysosomes is normal. In fact, in cultured skin fibroblasts the four N-glycans of GCase do
not acquire mannose-6-phosphate [71]. Following correct folding of newly formed GCase molecules
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in the ER, these bind to the membrane protein LIMP2 (lysosomal membrane protein 2) [72–74]. This
binding is mediated by hydrophobic helical interfaces on both proteins [75]. Action myoclonus renal
failure syndrome (AMRF) is a recessively inherited disease caused by mutations in LIMP2 [76]. In
most cell types of AMRF patients, except for phagocytic cells, GCase is markedly reduced due to faulty
transport to lysosomes [76,77]. More recently, progranulin (PGRN) was identified as another factor
influencing GCase [78,79]. PGRN is thought to function as a chaperone facilitating the transport of
GCase to lysosomes. It recruits heat shock protein 70 (HSP70) to the GCase/LIMP2 complex in the ER
and thus promotes delivery of GCase to lysosomes [80]. Another protein found to interact with newly
formed GCase in the ER is ERdj3 [81].
3.2. Catalytic Activity of GCase
The primary substrate of GCase is GlcCer, as is reflected by the prominent accumulation of
this lipid during GCase deficiency [82–84]. However, it recently has become apparent that catalytic
versatility of the enzymes needs consideration. Firstly, GCase was found able to hydrolyze artificial
β-xylosides [20]. Secondly, several retaining β-glycosidases are reported to be able to transglycosylate
when provided with a suitable aglycon acceptor (Figure 1B) [85]. Such catalytic activity has also
been observed for GCase, the enzyme being able to generate glucosylated cholesterol (GlcChol) by
transglucosylation [86–88]. This reaction occurs during cholesterol accumulation in lysosomes as
occurs in Niemann–Pick disease type C (NPC) [86]. Massive accumulation of GlcChol in the liver
of NPC mice was demonstrated. Inducing lysosomal cholesterol accumulation in cultured cells by
their exposure to U1986663A is accompanied by formation of GlcChol [86]. Of note, under normal
conditions GlcChol is primarily degraded by GCase into glucose and cholesterol. It may be envisioned
that further research will reveal that there exist more β-glucosidic metabolites being substrates (and
products) of GCase.
4. Gaucher Disease, Inherited Deficiency in GCase
4.1. Gaucher Disease, a Lysosomal Storage Disorder
Since degradation of GSLs is catalyzed by lysosomal glycosidases, inherited deficiencies
in these enzymes cause lysosomal accumulation of their GSL substrates, so-called
glycosphingolipidoses [9,41,89–91]. Examples of such disorders are Gaucher disease, Krabbe disease,
GM2-gangliosidosis, Sandhoff disease, and GM1-gangliosidosis. The glycosphingolipidoses are
clinically diverse and generally show marked heterogeneity in severity of disease that usually involves
neuropathy in more severely affected patients.
Gaucher disease is a prototype glycosphingolipidosis. The first case report was published in
1882 by Ernest Gaucher concerning a female patient with unexplained massive splenomegaly without
leukemia [3]. Soon it was recognized that this patient represented a distinct disease entity that was
subsequently referred to as Gaucher’s disease or Gaucher disease (GD). Following the demonstration
of abnormal accumulation of GlcCer in GD patients as the result of deficient GCase activity, the GBA
gene encoding the acid β-glucosidase was cloned and characterized [4]. The GBA gene is located
at locus 1q21 and neighbored by a pseudogene [92]. Numerous mutations in GBA have now been
associated with GD. The consequences of mutations at the level of the GCase protein may markedly
differ. For example, the common N370S GCase mutation among Caucasians results in near normal
production of a mutant enzyme with aberrant catalytic properties [93]. The heteroallelic presence of
this mutation protects against a neuronopathic disease course [4,44,94]. This GBA mutation occurs
relatively frequently among Ashkenazim and was proposed to offer some advantage against an
infectious disease, for example, bubonic plaque or tuberculosis [95–99]. In contrast, another common
pan-ethnic mutation encoding L444P GCase, results in a mutant enzyme that largely misfolds in the
ER and consequently only a small fraction (<10% of normal) reaches lysosomes. Homozygosity for the
L444P mutation is always associated with a severe neuronopathic disease manifestation [4]. The L444P
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mutation is thought to have arisen repeatedly by homologous recombination of the GBA gene with
its pseudogene.
The genetic heterogeneity of GD is accompanied by clinical heterogeneity of the disorder. Common
symptoms manifesting in GD patients are hepatosplenomegaly, hematological abnormalities like
anemia and thrombocytopenia, skeletal disease, and neuropathology. A very severe manifestation
(referred to as collodion baby) involves lethal skin barrier dysfunction [4]. Discrete phenotypic
variants of GD are historically discerned: type 1, the non-neuronopathic variant; type 2, the acute
neuronopathic variant; type 3, the subacute neuronopathic variant and the collodion baby or neonatal
variant. It was proposed to no longer adhere to this classification, but rather view GD as a continuum
of phenotypes [99]. Marked intraindividual variation occurs in type 1 GD patients in the nature and
degree of organ involvement and particular symptoms such as skeletal disease [4].
The correlation of GBA genotype with GD phenotype is limited in some aspects. While the
presence of N370S GCase protects GD patients against neuropathology, there are several reports of
monozygotic GD twins with discordant severity of visceral disease [100,101]. A very specific clinical
course is associated with the presence of D409H GCase involving yet unexplained cardiac symptoms,
including aortic valve, mitral valve, and ascending aorta calcifications [102–104].
Modifier genes, and possibly epigenetics and external factors, are considered to impact on the
clinical manifestation of GCase deficiency. The transmembrane protein CLN8 (ceroid-lipofuscinosis,
neuronal 8), recycling between the ER and Golgi apparatus, is a putative modifier [105]. CLN8,
identified as putative modifier of GD in a genome-wide association study, has recently been reported
to be involved in the transport of newly formed lysosomal enzymes between ER and Golgi [106]. Other
proteins are known to directly influence the life cycle and activity of GCase. Saposin C is the lysosomal
activator protein of GCase, and patients with a defective saposin C develop symptoms similar to
GD patients [68]. LIMP2, encoded by the SCARB2 (scavenger receptor class B, 2) gene, transporting
GCase to lysosomes was reported to be a GD modifier [107]. Polymorphisms in the UGCG gene coding
for GCS catalyzing synthesis of GlcCer have also been proposed as GD modifiers [108]. Recently,
microRNAs up- or downregulating GCase and downregulating LIMP2 were reported [109].
It has recently been appreciated that carrying a mutant GBA gene is not without health risk.
Carriers of GD have a yet unexplained significantly increased (20-fold) risk for developing Parkinson
disease (PD) and Lewy body dementia (LBD) [110–112]. A recent study in the United Kingdom
revealed that 5–25% of patients with PD carry glucocerebrosidase gene mutations, and 10–30%
of glucocerebrosidase carriers will develop PD by age 80 [113]. Of note, active GCase activity is
also decreased, and corresponding glycosphingolipid substrate levels elevated, in the brain in PD
without GBA1 mutations [114,115]. Abnormalities in multiple enzymes and other proteins involved in
sphingolipid metabolism were observed in association with PD [114,116,117]. With increasing age,
the brain of mice shows reduced GCase levels and increased amounts of lipid substrate [115]. PD is
historically viewed as a “proteinopathy” with cellular protein aggregates like that ofα-synuclein (αSyn).
It has more recently been hypothesized that sphingolipid abnormalities may be primary disturbances
that can produce protein aggregation [114]. Indeed, inactivation of GCase promotes accumulation of
αSyn aggregates [118]. It was observed that insoluble alpha-synuclein positive aggregates in sporadic
PD midbrain linearly correlate with loss of GCase activity [119]. Likewise, protein aggregates develop
in mice with primary GBA mutations [120]. Supplementation of GCase or reduction of accumulating
glycolipids prevents and reverses α-synucleinopathy [121,122]. It was furthermore observed that
over-expression of aggregating αSyn causes a reduction of GCase, suggesting a potential harmful
interaction between the two proteins in a self-amplifying manner [123–125]. In vitro experiments
showed that GCase and aSyn may directly interact at lysosomal pH [126]. Different explanations
have been proposed for ways by which mutant GCase may induce α-synucleinopathy (reviewed
in [125,127,128]). For example, it was hypothesized that the accumulation of substrates of GCase is
pathogenic; that GCase deficiency causes inhibition of autophagy and lysosomal degradative capacity
and subsequently reduces turnover of αSyn; that increased αSyn levels impair the activity of GCase
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and vice versa; and, that GCase deficiency impairs mitochondria. Contrarily, it was proposed that
mutant GCase protein may be toxic by inducing an excessive unfolded protein response in the ER or
saturating the ubiquitin–proteasome pathway [129,130]. It is conceivable that multiple mechanisms
may be involved in the GBA-PD pathology.
4.2. Lysosomal GlcCer Deposits in Macrophages: Gaucher Cells
The storage of GlcCer in GD patients occurs almost exclusively in macrophages residing in the
spleen, liver, bone marrow, lymph nodes, and lung (Figure 1C) [131]. The lipid-laden Gaucher cells
are viable, alternatively activated macrophages [132]. These cells overproduce and secrete specific
proteins resulting in massively elevated plasma levels in symptomatic GD patients. These proteins are
now used as biomarkers of body burden of Gaucher cells. The first identified plasma biomarker is the
chitinase named chitotriosidase encoded by the CHIT1 gene [133,134]. It can be conveniently detected
by the measurement of its activity towards 4-methylumbelliferyl-chitotrioside [133] and the superior
substrate 4-metylumbelliferyl-4′-deoxy-chitobioside [135,136]. Plasma chitotriosidase is on average
about 1000-fold elevated in type 1 GD patients. Immunohistochemistry and in situ hybridization
revealed that the enzyme is produced by Gaucher cells. Common is a 24-base-pair duplication in the
CHIT1 gene that excludes synthesis of active chitinase [137]. The chemokine CCL18/PARC (Chemokine
(C-C motif) ligand 18; Pulmonary and activation-regulated chemokine) serves as an alternative plasma
marker of Gaucher cells, being 20 to 50-fold elevated plasma of type 1 GD patients [138,139]. The
chemokine is over-produced and secreted by Gaucher cells [139]. More recently the glycoprotein
nonmetastatic melanoma protein B (gpNMB) was found to be overproduced by Gaucher cells [140].
A soluble fragment of gpNMB is released into plasma and is over 50-fold elevated in type 1 GD
patients [140,141]. In cerebral spine fluid and brain of type 3 GD patients elevated gpNMB levels
have also been observed [142]. Likewise, recently an increased level of gpNMB in the substantia
nigra of PD patients was reported [143]. In mice with conditional deficiency in GCase in the white
blood cell lineage Gaucher-like cells are formed. These do not produce chitotriosidase or CCL18, but
gpNMB does [140,144]. Inactivation of GCase with an irreversible inhibitor was found to increase
gpNMB in the brain [143]. Interestingly, zebrafish and fruit flies overproduce a chitinase during GCase
deficiency [130,145].
There is compelling evidence for a direct role of Gaucher cells in GD pathology. Their presence in
spleen, liver, and bone marrow is associated with splenomegaly, hepatomegaly, and hematological
abnormalities, respectively [4]. The same holds for these symptoms in GD mice with induced GCase
deficiency in white blood cells [144]. In GD spleens the storage lesions contain a core of mature
Gaucher cells surrounded by pro-inflammatory macrophages [132]. These lesions likely contribute
to the complex cytokine, chemokine, and protease abnormalities in GD patients [91,146,147]. Type 1
GD patients show low-grade inflammation and activation of both coagulation and the complement
cascade [148,149]. Of note, many of the visceral symptoms of type 1 Gaucher disease patients resemble
those of Niemann–Pick type A and B patients suffering from lysosomal acid sphingomyelinase
(ASMase) deficiency causing lysosomal sphingomyelin storage [42]. In both disorders, lipid storage in
visceral macrophages is a hallmark. In sharp contrast, while GCase is markedly reduced in most cell
types of LIMP2-deficient AMRF patients, their symptoms differ from those of type 1 Gaucher patients.
Likely this is due to the fact that macrophages of AMRF patients contain a high residual GCase and
consequently no lipid-laden macrophages are formed [77].
4.3. Therapies of Gaucher Disease: ERT, SRT, PCT/EET
The prominence of lipid-laden macrophages in GD and their relationship to pathology has
prompted the design of rational therapies aiming to prevent and/or correct the lipid-laden macrophages.
The first effective treatment designed for type 1 GD is enzyme replacement therapy (ERT) aiming to
supplement patient macrophages with lacking enzyme by repeated intravenous enzyme infusion [150].
Therapeutic GCase, nowadays recombinant but initially isolated from placenta, has enzymatically
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modified N-linked glycans with terminal mannose groups to favor uptake via the mannose receptor
(or another mannose-binding lectin) at the surface of tissue macrophages. Two weekly ERTs reverse
hepatosplenomegaly and hematological abnormalities in type 1 GD patients [67]. In addition, it
reduces storage cells in the bone marrow [151]. Present ERT does, however, not prevent neurological
symptoms due to the inability of enzyme to pass the blood brain barrier.
An alternative GD treatment is substrate reduction therapy (SRT) [152–154]. SRT aims to balance
synthesis of GlcCer with reduced GCase activity of GD patients. Oral inhibitors of GCS (Miglustat and
Eliglustat) are approved drugs. Eliglustat therapy resembles ERT in efficacy [155]. Brain-permeable
inhibitors of GCS are presently designed and tested [156]. The response to treatment of GD patients is
primarily monitored by clinical assessments. A retrospective evaluation revealed that reductions in
plasma chitotriosidase during ERT correlate with corrections in liver and spleen volumes, improvements
in hemoglobin, platelet count, and bone marrow composition [157]. Given the observed positive
outcome of bone marrow transplantation in type 1 GD patients, genetic modification of hematopoietic
stem cells was, and still is, seriously considered as therapeutic avenue [144].
At present there is still an unmet need for neuronopathic GD. Small compounds are actively
studied as potential therapeutic agents in this respect. One envisioned approach is pharmacological
chaperone therapy (PCT). Chemical chaperones are small compounds improving folding of mutant
GCase in the ER, thus increasing lysosomal enzyme levels. Current studies with ambroxol, a weak
inhibitor of GCase, indicate impressive reductions in spleen and liver volumes in ambroxol-treated
type 1 GD patients as well as clinical improvements in type 3 GD patients [158–160]. Another approach
is enzyme enhancement therapy with small compounds (EET). An example of this is arimoclomol, a
heat shock protein amplifier, found to improve refolding, maturation, and lysosomal activity of GCase
in GD fibroblasts and neuronal cells [161].
5. Metabolic Adaptations to Lysosomal GCase Deficiency
5.1. Formation of Glucosylsphingosine From Accumulating GlcCer
Important metabolic adaptations occur during GCase deficiency in lysosomes (Figure 1D) [162].
We demonstrated that part of the accumulating GlcCer is actively converted by lysosomal acid
ceramidase to glucosylsphingosine (GlcSph) [163]. GlcSph is sometimes also referred to as lyso-GL1
or lyso-GB1. It was earlier observed that GlcSph is increased in the brain and spleen of GD
patients [164,165]. We firstly reported an average 200-fold increased GlcSph level in plasma of
symptomatic type 1 GD patients [166]. Urine of GD patients also contains increased GlcSph
isoforms [167]. Pharmacological inhibition of GCase in cultured cells and zebrafish embryos causes a
rapid increase in GlcSph [168]. The quantitative detection of GlcSph in biological samples was improved
by o-phthaldialdehyde (OPA) derivatization and high-performance liquid chromatography [169].
Further improvement was reached by the introduction of LC-MS/MS (liquid chromatography-mass
spectrometry) employing an identical (13)C-encoded glucosylsphingosine standard [168]. Measurement
of elevated plasma GlcSph is now regularly used in the confirmation of GD diagnosis.
Excessive GlcSph in GD patients is believed to contribute to various symptoms. GlcSph was linked
to the common reduced bone mineral density (osteopenia) in GD patients by impairing osteoblasts [170].
It is reported to promote α-synuclein aggregation, a hallmark of Parkinson disease [171]. Antigenicity
of GlcCer, and possibly GlcSph, is thought to cause the common gammopathies in GD patients,
gammopathies that can lead to multiple myeloma [172]. The same lipids were proposed to activate the
complement cascade activation and associated local tissue inflammation [173]. GlcSph is hypothesized
to diminished cerebral microvascular density in mice, based on the observed interference of the lipid
with endothelial cytokinesis [174]. Earlier studies have provided evidence that GlcSph promotes lysis
of red blood cells, impairs cell fission during cytokinesis, damages specific neurons, interferes with
growth, and activates pro-inflammatory phospholipase A2 (see for a review [91]). In line with these
observations is the occurrence of hemolysis, multinucleated macrophages, neuropathology, growth
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retardation, and chronic low-grade inflammation in GD patients [4]. Of note, in the brain of ageing mice
reduction of active GCase in combination with increased glucosylceramide and glucosylsphingosine
levels were observed [116].
The conversion of accumulating GSL in lysosomes to glycosphingoid bases (lyso-lipids) is not
unique to Gaucher disease. Comparable acid ceramidase-dependent formation of sphingoid bases
occurs in Krabbe disease (galactosylsphingosine), Fabry disease (globotriaosylsphingosine; lysoGb3),
GM2-gangliosidosis (lysoGM1), and GM2-gangliosidoses (lysoGM2) [91,175]. In Niemann–Pick disease
types A and B, the water soluble lysoSM is formed from accumulating SM [176]. As for GlcSph in GD,
toxicity of excessive galactosylsphingosine in Krabbe disease and excessive lysoGb3 in Fabry disease
have been proposed [91,177–182].
5.2. Excessive Gangliosides
In GD patients increases of the ganglioside GM3 (monosialodihexosylganglioside) in plasma and
spleen were observed [183]. It is unknown whether this abnormality is caused by increased metabolic
shuttling of newly formed GlcCer to gangliosides and/or impaired recycling of gangliosides. Not
surprisingly (see Section 2.1), the elevated concentrations of GM3 in GD patients are accompanied by
insulin insensitivity, without overt hyperglycemia [184].
5.3. Increased Activity of Cytosol-Faced GBA2 and GlcChol
Besides GCase, cells contain another retaining β-glucosidase that metabolizes GlcCer. The
enzyme GBA2 was discovered during studies with GCase-deficient cells [21]. GBA2 is synthesized as
soluble cytosolic protein that rapidly associates to the cytosolic leaflet membranes with its catalytic
pocket inserted in the lipid layer. GBA2 shows prominent transglucosylase capacity and is largely
responsible for the (reversible) formation of GlcChol from GlcCer and cholesterol [86]. The GBA2 gene
(locus 1p13) was identified and GBA2-deficient mice have meanwhile been generated [185,186]. The
animals develop normally without overt abnormality, except for incidences of male infertility [185].
GBA2-deficient zebrafish also develop normally [168]. Inhibition of GBA2 in GD and NPC patients
treated with N-butyldeoxynojirimycin causes no major complications, whereas on the other hand,
individuals with spastic paraplegia and cerebellar ataxia were found to be GBA2 deficient [187–190].
The physiological role of the highly conserved GBA2 is still an enigma [191].
Reducing GBA2 activity, genetically or using small compound inhibitors such AMP-DNM, has
remarkable beneficial effects in NPC mice, ameliorating neuropathology and prolonging lifespan
significantly [52,53]. A comparable neuro-protective effect of the iminosugar AMP-DNM was also
observed in mice with Sandhoff disease, another neuropathic glycosphingolipidosis [54]. Presently
zebrafish models are used to study the poorly understood interplay between GCase and GBA2-mediated
metabolism of GlcCer [168]. The possible toxic effect of excessive glucosylated metabolites generated
by GBA2 during GCase deficiency warrants further investigation.
6. Part 2: GCase and Glucosylceramide Metabolism Beyond the Lysosome
6.1. GCase: Other Locations Than Lysosomes
As discussed in Section 3.1, GCase does not rely on mannose-6-phosphate receptor-mediated
intracellular sorting and re-uptake after secretion. The intracellular transport of GCase is tightly
governed by the membrane protein LIMP2 and secretion of GCase into the extracellular space is
normally prevented [77]. Immuno-electron microscopy has revealed that specific organelles are
involved in trafficking of GCase-LIMP2 complexes from the Golgi apparatus to lysosomes [192]. The
delivery of GCase to other locations than lysosomes warrants consideration and discussion.
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6.2. Lysosome-Related Organelles
To fulfill specific physiological functions several cell types have adapted their endolysosomal
apparatus and evolved specialized secretory compartments, the lysosome-related organelles (LROs)
(for reviews see [193,194]). The LROs are diverse and comprise endothelial cell Weibel-Palade bodies,
cytotoxic T cell lytic granules pigment cell melanosomes, and platelet dense and alpha granules.
Common components of LROs are tetraspanin CD63, and GTPases RAB27A or RAB27B. The same
proteins also occur in multivesicular endosomes (MVEs) that excrete intraluminal vesicles (ILVs) as
exosomes upon fusion with the plasma membrane [195]. The notochord vacuole in the zebrafish is
also considered to be an LRO [196,197]. Interestingly, LIMP2, the GCase transporter protein, was
implicated in the formation of this LRO [198].
An established link between GSLs and LROs concerns the pigmented melanosomes in melanocytes.
The formation of melanosomes requires GSLs: melanoma cells when deficient in GCS lose pigmentation
due to aberrant transport of the enzyme tyrosinase synthesizing melanin [199]. Similarly, cultured
melanocytes lose pigmentation when treated with a GCS inhibitor (Smit and Aerts, unpublished
observations).
Keratinocytes contain a special kind of LRO, the lamellar body (LB), which justifies more detailed
discussion regarding GSLs and their metabolism (see Sections 8 and 9). Prior to this, the composition
of the mammalian skin is introduced in the section below.
7. Composition of the Skin
7.1. Skin Differentiation and Barrier Formation
The mammalian skin acts as a key barrier offering protection against xenobiotics and harmful
pathogens and preventing excessive water loss from the body (Figure 2A) [200]. The barrier function
resides in the epidermis, the outermost part of the skin that consists of four distinct layers: the stratum
basale (SB), stratum spinosum (SS), stratum granulosum (SG), and stratum corneum (SC) [201]. The
innermost SB, SS, and SG are the vital parts of the epidermis (thickness: 50–100 µm) while the SC is the
non-vital differentiation product (thickness: 10–20 µm). The SB contains proliferating keratinocytes
that after escape from this single cell layer start to differentiate and migrate towards the SC, where the
keratinocytes differentiate to terminal corneocytes. During this differentiation process the keratinocytes
flatten and diminish their water content. During the flattening process cells become filled with keratin.
At the interface between the SG and SC, subcellular structures like organelles and nuclei are degraded
and corneocytes are formed (as reviewed in [202]).
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Figure 2. Schematic overview of the human skin and the main processes involved around GCase and its
related lipids. (A) Schematic overview of a cross section of the skin showing the epidermis, dermis and
subcutaneous tissue. The middle illustration shows a more detailed view of the epidermis under healthy
conditions. The right illustration depicts a more detailed view of the epidermis with a reduced barrier.
Exogenous compounds can get into deeper layers of the pidermis when the bar ier is reduced, resulting
in an immune respo se. It also leads to an increased transepidermal water los (TEWL). (B) Schematic
overview of the main processes nvolved around GCase within the cell. Arrows indicate the transport
or conversion of lipids; associated enzymes are listed adjacent to thei abbreviations. ASAH1:
acid ceramidase, AS 2: neutral cera idase, SMase: acid sphingo yelinase, CERS: ceramide
synthase family, CSase: cholesterol sulfatase, DES1/2: dihydroceramide desaturase 1 and 2, ELOVL:
elongation of very long chain fatty acids family, FAS: fatty acid synthase, GCase: β-glucocerebrosidase,
GCS: glucosylceramide synthase, KSR: 3-ketosphinganine reductase, PLA-2: phospholipase, SCD:
stearoyl-CoA desaturase, SMS: sphingomyelin synthase, SPT: serine palmitoyltransferase, SULT:
cholesterol sulfotransferase type 2 isoform 1b.
J. Clin. Med. 2020, 9, 736 12 of 30
7.2. Stratum Corneum: Hydration and Skin-pH
Proper function and features of the SC are dependent on optimal water content and acidity. The
SC hydration level depends on multiple factors such as amino acids, specific sugars and salts, referred
to as the natural moisturizing factor (NMF) [203]. Amino acids of the NMF are breakdown products
of the major SC protein filaggrin. Mutations in the filaggrin gene FLG cause a reduced NMF level
associated with dry skin [204,205]. NMF also plays a key role in maintenance of pH in the SC. At the
outside of the SC the pH is 4.5–5.3 and it gradually increases to pH 6.8 in the inner SC [206]. The local
pH likely modulates the activity of various enzymes in the SC, including GCase and ASMase, with
optimal catalytic activity at a more acid pH, and thus also impacts on lipid structures [207].
7.3. Stratum Corneum: Composition
The SC has a “brick-and-mortar” like structure, where the corneocytes are the “bricks” embedded
in a lipid matrix that is the “mortar” of the SC [206,208]. During the terminal differentiation of
corneocytes, plasma membranes develop into the cornified lipid envelope, a lipid-linked crosslinked
protein structure [209]. The cornified lipid envelope acts as template for the formation and organization
of extracellular lipid lamellae [210,211]. The lipid matrix contains approximately on a total lipid
mass basis 50% ceramides, 25% cholesterol, and 15% free fatty acids with very little phospholipid.
The adequate balance of lipid components is essential for proper lipid organization and SC barrier
competence [212]. Alterations in the lipid composition have been associated to various skin diseases,
particularly to psoriasis, atopic dermatitis and several forms of ichthyosis [213–218].
8. Sphingolipids of the Stratum Corneum
8.1. Role of Lamellar Bodies
Keratinocytes having specific ovoid-shaped LROs with a diameter of about 200 nm are called
lamellar bodies (LBs), or alternatively lamellar granules, membrane-coating granules, cementsomes, or
Odland bodies [219]. LBs have a bounding membrane surrounding lipid disks. The main lipids packed
in LBs are precursors of ceramides and fatty acids constituting the lamellar matrix in the SC. In the
uppermost granular cells, the bounding membrane of the LB fuses into the cell plasma membrane, and
the lipid disks are extruded into the intercellular space between the SC and SG. The initially extruded
content of the LB is largely metabolized to ceramides and fatty acids and rearranged to form together
with cholesterol the intercellular lamellae of the SC.
Keratinocytes serve as the initial factory of the permeability barrier of the skin [219]. Briefly,
the generation of SC barrier lipids initiates in keratinocytes, where ceramides are de novo formed
by ceramide synthase 3 (CerS3). The sphingolipid content of keratinocytes increases along with
differentiation. Newly formed ceramides are rapidly modified into glucosylceramides (GlcCers) and
sphingomyelins (SMs), thereby likely protecting keratinocytes from cytotoxic ceramide effects. Next,
these sphingolipids are packaged into LBs [212]. The membrane protein ABCA12 (ATP-binding
cassette sub-family A member 12) is essential for the presence of GlcCer in LBs [220–222]. Several
mutations in the ABCA12 gene cause Harlequin-type ichthyosis, characterized by thickened skin over
nearly the entire body at birth and causing early death. Incorporated in LBs besides lipids are also acid
hydrolases including GCase, ASMase, and phospholipase A as well as proteases and antimicrobial
peptides. Following exocytotic secretion of LBs, the SM and GlcCer molecules are largely enzymatically
re-converted to ceramides [223,224].
8.2. Chemical Composition of Skin Sphingolipids
The sphingolipids in the skin differ in their complexity of chemical composition from those
encountered in most tissues. Firstly, their sphingosine backbones are modified to yield from
dihydroceramide (DS) precursors not only the regular ceramide (S) but 6-hydroxyceramide (H),
phytoceramide (P) and 4,X-dihydroxysphinganine containing ceramide (T), as well [225–228]. In
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addition, skin ceramides have unique fatty acyl moieties. Besides regular non-hydroxylated fatty acyls
of variable chain length, there are α-hydroxylated andω-esterified structures (acylceramides) [229].
In keratinocytes, fatty acids can be elongated by elongases (mainly ELVOL1, ELVOL4, and
ELVOL6) [230,231]. Very long chain fatty acids are incorporated in phospholipids and sphingolipids
are packaged in LBs. Cholesterol does not require a conversion to be transported into LBs. Cholesterol
can furthermore be metabolized to oxysterol or cholesterol sulfate. Oxysterol and cholesterol sulfate can
both stimulate keratinocyte differentiation, additionally, cholesterol sulfate has a key role in [232–235].
Since cholesterol sulfate is highly amphiphilic it can cross the cell membrane and directly enter the SC,
where it is metabolized by LB-derived steroid sulfatase to cholesterol [236,237]. Because cholesterol
sulfate inhibits proteases that are involved in desquamation [238], its decrease in the upper layers of
the SC results in the initiation of desquamation [239,240].
Besides the presence of regular ceramides, the scaffold of the lipid matrix in the SC is built of
acylceramides, containingω-hydroxylated very long chain fatty acids acylated at theω-position with
linoleic acid [212,228]. Also, the acylceramides are synthetized in the keratinocytes, where they and
regular ceramides are glucosylated at Golgi membranes and secreted via LB secretion. Extracellularly
the linoleic acid residues are replaced by glutamate residues at proteins exposed on the surface of
corneocytes, thus completing the corneocyte lipid envelope [212,228,241].
9. GCase: Crucial Extracellular Role in the Skin
Inhibition of either cholesterol, phospholipid, ceramide or glucosylceramide synthesis prevents
the delivery of lipids into LBs, disrupting LB formation, thereby impairing barrier homeostasis
(Figure 3) [242]. LB secretion and lipid structure is abnormal in the outer epidermis of multiple
skin diseases, like Atopic Dermatitis and Netherton syndrome [215,243,244]. A complete lack of
GCase results in a disease phenotype (collodion baby) with fatal skin abnormalities and inhibition
of GCase activity reduces the permeability barrier formation [245–248]. Gaucher mice homozygous
for a null allele develop skin abnormalities that are lethal within the first day of life [6,7]. Holleran
and colleagues showed increased trans-epidermal water loss (TEWL) and altered barrier function in
GCase-deficient mice [248], suggesting deficient conversion of GlcCer to ceramides by GCase alters the
skin barrier function. Identical changes were observed in hairless mice treated with GCase inhibitor
bromoconduritol B epoxide, however, ceramide levels remained normal [246,248]. Similarly, mice
deficient for prosaposin, and therefore also lacking the GBA activator protein saposin C, accumulate
GlcCer in the SC and show abnormal SC lamellar membrane structures [249]. Interestingly, deficiency
of LIMP2 in AMRF patients is not associated with skin abnormalities. No prominent abnormalities
have also been noted in LIMP2-deficient mice. Apparently, GCase is reaching the SC sufficiently
without its regular transporting protein.
GlcCer and GBA appear to be co-localized in the LB [250–252]. GBA activity has been observed
throughout the outer parts of the epidermis [253–255], and recently a novel in situ method with the use
of activity-based probes (ABPs) confirmed predominant localization of active GBA in the extracellular
space of the SC lipid matrix [256].
GD is not the only lysosomal storage disease associated with skin barrier abnormalities. In
Niemann–Pick disease a deficiency in ASMase causes an impaired conversion of SM into ceramides in
the SC and, therefore, into a disturbed skin barrier [248,257]. Reduction of epidermal ASMase activity
by the inhibitor imipramine causes delayed permeability barrier repair after SC injury [258].
J. Clin. Med. 2020, 9, 736 14 of 30J. Clin. Med. 2020, 9, 736  14  of  29 
 
 
Figure 3. The life cycle of GCase in and beyond the lysosome. AMRF: Action myoclonus renal failure 
syndrome,  ER:  endoplasmic  reticulum,  LB:  lamellar  body,  LIMP2:  lysosomal membrane  protein 
2LRO: lysosome related organelle. 
10. Atopic Dermatitis 
A common skin disease is atopic dermatitis (AD, OMIM #603165). Clinical manifestation of AD 
involves eczematous  lesions as well as erythema, xerosis, and pruritis  [259–261]. In AD  there  is a 
complex  interplay between  inflammation, genetic background, and the skin barrier. Inflammation 
can  affect  the  skin barrier,  and  subsequent  entry  of  compounds promotes  an  immune  response. 
Additionally, it was observed that AD is associated with loss of function mutations in the filaggrin 
gene FLG [262,263]. As discussed in Section 7.2, filaggrin is essential for SC hydration and may affect 
the sensitivity of the skin [264]. Even though FLG mutations have been suggested as a predisposing 
factor for AD, they do not influence SC ceramide synthesis [264–266]. 
10.1. SC Lipids in AD 
SC lipid metabolism and composition have been substantially studied in AD, however there is 
some disagreement in literature about the lipid composition in the skin of AD patients. Farwanah 
and co‐workers  reported no change  in non‐lesional AD skin compared  to control  [267], although 
other studies report a decrease  in  total ceramide  level, as well as an  increase  in ceramide  (AS) and a 
decrease  in  ceramide  (EOS)  and  (EOH),  mainly  in  lesional  AD  skin  compared  to  control 
[215,266,268–271]. Additionally, Di Nardo et al. have reported a decrease in ceramide/cholesterol ratio in 
AD skin [271]. 
Besides subclass composition ceramide chain length has also been studied in AD. Some report 
an increase of short chain ceramides (total chain length of 34 carbon atoms) in lesional AD skin that 
also  correlated  with  an  increased  TEWL  [268,272].  Moreover,  levels  of  ω‐O‐acyl‐ceramides 
correlated  negatively with  TEWL  [268]. A  reduction  in  ω‐O‐acyl‐ceramide  in AD  compared  to 
control was also reported by  Jungersted et al. They additionally observed no statistical difference 
between their FLG mutant and wild‐type group in relation to the ω‐O‐acyl‐ceramide decrease [266]. 
Data on fatty acids in relation to AD skin are limited, but there are a few reports reporting a 
reduced  fatty acid chain  length  [273,274]. A study by van Smeden et al. described an  increase of 
Figure 3. The life cycle of GCase in and beyond the lysosome. AMRF: Action myoclonus renal failure
syndrome, ER: endoplasmic reticulum, LB: lamellar body, LIMP2: lysosomal membrane protein 2LRO:
lysosome related organelle.
10. Atopic Dermatitis
A common skin disease is atopic dermatitis (AD, OMIM #603165). Clinical manifestation of AD
involves eczematous lesions as well as erythema, xerosis, and pruritis [259–261]. In AD there is a
complex interplay between inflammation, genetic background, and the skin barrier. Inflammation
can affect the skin barrier, and subsequent entry of compounds promotes an immune response.
Additionally, it was observed that AD is associated with loss of function mutations in the filaggrin
gene FLG [262,263]. As discussed in Section 7.2, filaggrin is essential for SC hydration and may affect
the sensitivity of the skin [264]. Even though FLG mutations have been suggested as a predisposing
factor for AD, they do not influence SC ceramide synthesis [264–266].
10.1. SC Lipids in AD
SC lipid metabolism and composition have been substantially studied in AD, however there is
some disagreement in literature about the lipid co position in the skin of AD patients. Farwanah
and co-workers reported no change in non-lesional AD skin compared to control [267], although other
studies report a dec ease in total ceramid level, as well as an increase in ceramide (AS) and a decrease
in c ramide (EOS) and (EOH , mainly in lesiona AD skin compared to control [215,266,268–271].
Additionally, Di Nar o et al. have report d a decrease in ceramide/cholesterol rati in AD skin [271].
Besides subclass composition ceramide chain length has also been studied in AD. Some report
an increase of short chain ceramides (total chain length of 34 carbon atoms) in lesional AD skin that
also correlated with an increased TEWL [268,272]. Moreover, levels ofω-O-acyl-ceramides correlated
negatively with TEWL [268]. A reduction inω-O-acyl-ceramide in AD compared to control was also
reported by Jungersted et al. They additionally observed no statistical difference between their FLG
mutant and wild-type group in relation to theω-O-acyl-ceramide decrease [266].
Data on fatty acids in relation to AD skin are limited, but there are a few reports reporting a
reduced fatty acid chain length [273,274]. A study by van Smeden et al. described an increase of
shorter fatty acids, mainly saturated fatty acids with 16 and 18 carbon atoms, as well as a reduction
in fatty acids with 24 carbons or more in non-lesional AD patients [273]. However, another study
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observed an increased level of very long fatty acid chains in non-lesional as well as lesional AD [274].
It was hypothesized that SC ceramides and fatty acids share a common synthetic pathway, and this is
consistent with the observation that ceramide composition is paralleled by the chain length of fatty
acids [275].
The expression of enzymes involved in the biosynthesis of fatty acids and ceramides was related
to the SC lipid composition in lesional AD skin [276]. Danso et al. observed an altered expression of
GBA, ASMase, and CerS3 in lesional AD skin with a corresponding increase in ceramide (AS) and (NS)
and decrease in esterifiedω-hydroxy CERs. Additionally, they noted increased levels of unsaturated
fatty acids and reduced levels of C22–C28 fatty acids in combination with an altered expression of
stearoyl CoA desaturase (SCD) and elongase 1 (ELOVL1) [276].
10.2. Potential Role for Glucosylsphingosine in AD Pathology
Deficiency of ceramides in the SC is thought to contribute to the dry and barrier-disrupted skin
of patients with AD. It was proposed that this deficiency involves a tentative novel enzyme named
sphingomyelin-glucosylceramide deacylase, forming sphingosylphosphorylcholine (SPC; lysoSM) and
GlcSph from SM and GlcCer. Increased deacylase activity is thought to contribute to reduced formation
and subsequent deficiency of ceramide in the AD skin [277]. The deacylase enzyme is considered to be
distinct from acid ceramidase as based by apparent isoelectric point [278]. Increased deacylase activity
was observed for involved SC and epidermis in patients with AD [279]. Unfortunately, the deacylase
has so far not been isolated and characterized. At present it cannot be excluded that the intriguing
observations are explained by some neutral ceramidase, a bacterial amidase, or even acid ceramidase
that in lipid-laden macrophages of GD patients shows GlcCer deacylase activity.
A common symptom in AD is pruritis. It was observed that GlcSph induces scratching in mice and
more recently it was demonstrated that GlcSph activates the Serotonin Receptor 2 a and b, considered
to be part of a novel itch signaling pathway [280,281].
10.3. Direct Role of GCase in AD?
As discussed above, GCase expression was found to be altered in (particularly lesional) AD
skin [276]. However, no abnormality in GCase activity level in AD skin was previously noted [282].
Earlier research in mice pointed to changes in location of GCase activity in mice with a skin barrier
disruption [246]. Using the specific and sensitive ABP technology, the localization of active GCase
molecules in AD skin has been studied. An abnormal GCase localization in (mainly lesional) AD
skin was observed together with abnormal SC lipids (Boer, submitted for publication). It will be of
interest to comparably study other skin diseases. It should be stressed that abnormalities in GCase are
not a sole cause for AD, however, an acquired local abnormal enzyme activity might contribute to
the pathology.
11. Summary and Conclusions
This review addresses the multiple functions of the enzyme GCase that degrades the ubiquitous
glycosphingolipid GlcCer. In the first part of the review, the metabolism and various functions of
glycosphingolipids in health and disease are discussed. The structural features and catalytic mechanism
of GCase are described, as well as its remarkable life cycle involving LIMP2-mediated transport to
lysosomes. The essential cellular role of GCase in turnover of GlcCer in lysosomes is illustrated
by the lysosomal storage disorder Gaucher disease (GD), which results from an inherited GCase
deficiency. The review describes the variable symptoms of GD patients and the presumed underlying
pathophysiological mechanisms. In addition, it addresses the presently available treatments of visceral
manifestations of GD. In the second part of the review, attention is focused on another, extracellular,
role of GCase in the skin. In the stratum corneum, GCase converts secreted GlcCer to ceramide, an
essential component of lipid lamellae contributing to the barrier properties of the skin. A major lack of
GCase activity causes a lethal skin pathology, the collodion baby.
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To conclude, the catalytic ability of the enzyme GCase has been exploited in evolution for two
different functions: in lysosomes, it essentially contributes to cellular glycosphingolipid metabolism,
and in the extracellular space of the stratum corneum, it generates an essential building block for
lipid lamellae.
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